Comparison of maternal ghrelin and leptin in healthy mothers and mothers with Type 1 diabetes
Kos, Katarina, Syn, W. -K., Lewandowski, K. C., Bennett, J., Nwokolo, Chuka U., O'Hare, J. Paul and Randeva, Harpal S.. (2008) Comparison of maternal ghrelin and leptin in healthy mothers and mothers with Type 1 diabetes. Diabetic Medicine, Vol.25 (No.12). pp. 1400-1405. ISSN 0742-3071Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1464-5491.2008.02604.x
Maternal leptin affects placental growth hormone (GH), whereas ghrelin, a natural ligand of the growth-hormone-secretagogue receptor, modulates GH action. Both hormones may affect fetal growth, and dysregulation in diabetes may lead to fetal growth disturbances. The aim was to investigate changes in maternal ghrelin during pregnancy with diabetes and to establish reference leptin levels. Twelve healthy non-diabetic (ND) and 12 pregnant women with Type 1 diabetes (T1DM) were recruited. Age and body mass index (BMI) [ND: age 29.9 +/- 4.7 years (mean +/- sd), BMI 25.2 +/- 3.7 kg/m(2); T1DM: age 31 +/- 5.5 years, BMI 27 +/- 3.1 kg/m(2)] were similar in the groups. HbA(1c) in T1DM was 6.2 +/- 1.1% at 20 weeks, 6.3 +/- 1.1% at 30 weeks' gestation and 7.8 +/- 2.1% postpartum. Fasting plasma ghrelin, total leptin, free leptin (FL) and soluble leptin receptor (sOB-R) levels were measured at 20 and 30 weeks' gestation and postpartum and determined by radioimmunoassay. All pregnancies resulted in full-term singleton births with no differences in birth weight between groups [T1DM: 3.4 +/- 0.56 kg (mean +/- SE); ND: 3.6 +/- 0.3 kg, P = NS]. Ghrelin levels were lower in T1DM when corrected for age and mothers' weight (T1DM: 458 +/- 36 pg/ml and 432.9 +/- 26.6 pg/ml; ND: 562 +/- 52 pg/ml and 515.8 +/- 63 pg/ml at 20 and 30 weeks, respectively, P < 0.05). T1DM mothers had higher levels of sOB-R and FL levels declined at 30 weeks' gestation in T1DM (P = 0.04) but not in ND. In a population of pregnant women with expected changes in leptin levels as previously reported, ghrelin levels were lower in T1DM pregnancies at 20 and 30 weeks. This may have implications for fetal development and requires further study in diabetes, particularly in pregnancies that result in macrosomia. Diabet. Med. 25, 1400-1405 (2008).
|Item Type:||Journal Article|
|Subjects:||Q Science > QP Physiology
R Medicine > RG Gynecology and obstetrics
|Divisions:||Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Leptin, Ghrelin, Diabetes in pregnancy|
|Journal or Publication Title:||Diabetic Medicine|
|Number of Pages:||6|
|Page Range:||pp. 1400-1405|
|Access rights to Published version:||Restricted or Subscription Access|
|References:||1 Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660. 2 Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 2003; 144: 967–974. 3 Gualillo O, Caminos J, Blanco M, Garcia-Caballero T, Kojima M, Kangawa K et al. Ghrelin, a novel placental-derived hormone. Endocrinology 2001; 142: 788–794. 4 Palik E, Baranyi E, Melczer Z, Audikovszky M, Szocs A, Winkler G et al. Elevated serum acylated (biologically active) ghrelin and resistin levels associate with pregnancy-induced weight gain and insulin resistance. Diabetes Res Clin Pract 2007; 76: 351–357. 5 Nakahara K, Nakagawa M, Baba Y, Sato M, Toshinai K, Date Y et al. Maternal ghrelin plays an important role in rat fetal development during pregnancy. Endocrinolgy 2006; 147: 13333–13342. 6 Evers IM, de Valk HW, Mol BW, ter Braak EW, Visser GH. Macrosomia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia 2002; 45: 484–489. 7 Ng PC, Lee CH, Lam CW, Wong E, Chan IH, Fok TF. Plasma ghrelin and resistin concentrations are suppressed in infants of insulindependent diabetic mothers. J Clin Endocrinol Metab 2004; 89: 5563–5568. 8 Coutant R, Boux de Casson F, Douay O, Mathieu E, Rouleau S, Beringue F et al. Relationships between placental GH concentration and maternal smoking, newborn gender, and maternal leptin: possible implications for birth weight. J Clin Endocrinol Metab 2001; 86: 4854–4859. 9 Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephen TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. N Engl J Med 1996; 334: 292–295. 10 McConway MG, Johnson D, Kelly A, Griffin D, Smith J, Wallace AM. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000; 37: 717–723. 11 Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 2002; 51: 2105–2112. 12 Lewandowski K, Horn R, O’Callaghan C, Dunlop D, Medley GF, O’Hare P et al. Free leptin, bound leptin, and soluble leptin receptor in normal and diabetic pregnancies. J Clin Endocrinol Metab 1999; 84: 300–306. 13 Lewandowski K, Randeva HS, O’Callaghan CJ, Horn R, Medley GF, Hillhouse EW et al. Effects of insulin and glucocorticoids on the leptin system are mediated through free leptin. Clin Endocrinol 2001; 54: 533–539. 14 Randeva HS, Vatish M, Tan BK, Qureshi Z, Boovalingam P, Lewandowski KC et al. Raised plasma adiponectin levels in Type 1 diabetic pregnancies. Clin Endocrinol 2006; 65: 17–21. 15 Liu C, Liu X, Barry G, Ling N, Maki RA, De Souza EB. Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology 1997; 138: 3548–3554. 16 Kratzsch J, Knerr I, Galler A, Kapellen T, Raile K, Korner A et al. Metabolic decompensation in children with Type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor. Eur J Endocrinol 2006; 155: 609–614. 17 Clausen T, Burski TK, Oyen N, Godang K, Bollerslev J, Henriksen T. Maternal anthropometric and metabolic factors in the first half of pregnancy and risk of neonatal macrosomia in term pregnancies. A prospective study. Eur J Endocrinol 2005; 153: 887–894. 18 Verhaeghe J, Pintiaux A, Van Herck E, Hennen G, Foidart JM, Igout A. Placental GH, IGF-I, IGF-binding protein-1, and leptin during a glucose challenge test in pregnant women: relation with maternal body weight, glucose tolerance, and birth weight. J Clin Endocrinol Metab 2002; 87: 2875–2882. 19 Scholl TO, Stein TP, Smith WK. Leptin and maternal growth during adolescent pregnancy. Am J Clin Nutr 2000; 72: 1542–1547. 20 Verhaeghe J, van Bree R, Van Herck E. Maternal body size and birth weight: can insulin or adipokines do better? Metabolism 2006; 55: 339–344. 21 Pighetti M, Tommaselli GA, D’Elia A, Di Carlo C, Mariano A, Di Carlo A et al. Maternal serum and umbilical cord blood leptin concentrations with fetal growth restriction. Obstet Gynecol 2003; 102: 535–543. 22 King JC, Butte NF, Bronstein M, Kopp L, Lindquist SA. Energy metabolism during pregnancy: influence of maternal energy status. Am J Clin Nutr 1994; 53: 439–445S. 23 Lea RG, Howe D, Hannah LT, Bonneau O, Hunter L, Hoggard N. Placental leptin in normal, diabetic and fetal growth-retarded pregnancies. Mol Hum Reprod 2000; 6: 763–769. 24 Erdmann J, Lippl F, Wagenpfeil S, Schusdziarra V. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and Type 2 diabetes. Diabetes 2005; 54: 1371–1378. 25 Fuglsang J, Skjaerbaek C, Espelund U, Frystyk J, Fisker S, Flyvbjerg A et al. Ghrelin and its relationship to growth hormones during normal pregnancy. Clin Endocrinol 2005; 62: 554–559. 26 Hytten FE, Chamberlain G. Clinical Physiology in Obstetrics. Oxford, UK: Blackwell Scientific Publications, 1991. 27 Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier, JC, Huston- Presley L, Friedman JE et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 2002; 51: 2207–2213. 28 Kitamura S, Yokota I, Hosoda H, Kotani Y, Matsuda J, Naito E et al. Ghrelin concentration in cord and neonatal blood: relation to fetal growth and energy balance. J Clin Endocrinol Metab 2003; 88: 5473–5477. 29 Gohlke BC, Huber A, Hecher K, Fimmers R, Bartmann P, Roth CL. Fetal insulin-like growth factor (IGF)-I, IGF-II, and ghrelin in association with birth weight and postnatal growth in monozygotic twins with discordant growth. J Clin Endocrinol Metab 2005; 90: 2270–2274. 30 Bouhours-Nouet N, Boux de Casson F, Rouleau S, Douay O, Mathieu E, Bouderlique C et al. Maternal and cord blood ghrelin in the pregnancies of smoking mothers: possible markers of nutrient availability for the fetus. Horm Res 2006; 66: 6–12. 31 Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D et al. Perinatal mortality and congenital anomalies in babies of women with Type 1 or Type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006; 333: 177. 32 Penney GC, Mair G, Pearson DW; Scottish Diabetes in Pregnancy Group. Outcomes of pregnancies in women with Type 1 diabetes in Scotland: a national population-based study. BJOG 2003; 110: 315– 318|
Actions (login required)